Journal
ANNALS OF THORACIC SURGERY
Volume 92, Issue 2, Pages 470-477Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.athoracsur.2011.04.065
Keywords
-
Funding
- NHLBI NIH HHS [T32 HL007849, 1K08HL094704-01, 2T32HL007849-11A1, T32 HL007849-11A1, K08 HL094704, R01 HL098526] Funding Source: Medline
Ask authors/readers for more resources
Background. Development of bronchiolitis obliterans syndrome (BOS) after lung transplantation confers increased patient morbidity and mortality. Fibrocytes are circulating bone marrow-derived mesenchymal cell progenitors that influence tissue repair and fibrosis. Fibrocytes have been implicated in chronic pulmonary inflammatory processes. We investigated the correlation of circulating fibrocyte number with BOS development in lung transplant patients. Methods. We prospectively quantified circulating fibrocyte levels among lung transplant patients. Patients were stratified according to the development of BOS as indicated by predicted forced expiratory volume in 1 second. Fibrocyte activity was analyzed by flow cytometry (cluster of differentiation 45(+), collagen 1(+)) in a blinded manner related to clinical presentation. Results. Thirty-nine patients (61.5% men) underwent double (33.3%), left (25.6%), or right (41.0%) lung transplantation. Average patient age was similar between BOS and non-BOS patients (58.3 +/- 3.9 vs 60.3 +/- 2.0 years, p = 0.67). Chronic obstructive lung disease was the most common indication for lung transplantation (41.0%). Median forced expiratory volume in 1 second was lower among BOS patients compared with non-BOS patients (1.08 vs. 2.18 L/s, p = 0.001). Importantly, circulating fibrocyte numbers were increased in BOS patients compared with non-BOS patients (8.91 vs 2.96 x 10(5) cells/mL, p = 0.03) by flow cytometry and were incrementally increased with advancing BOS stage (p = 0.02). Conclusions. Increased circulating fibrocyte levels correlate with the development of BOS after lung transplantation and positively correlate with advancing BOS stage. Quantification of circulating fibrocytes could serve as a novel biomarker and possible therapeutic target for BOS development in lung transplant patients. (Ann Thorac Surg 2011;92:470-7) (C) 2011 by The Society of Thoracic Surgeons
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available